Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916843 | 0.92 | MAPT (0.47) | MAPTKMT2AUSP2ALDH1A1ALOX15 | |
| SCHEMBL4922258 | 0.91 | MAPT (0.47) | MAPTKMT2AUSP2ALDH1A1ALOX15 | |
| SCHEMBL4922649 | 0.89 | PTGDR (0.41) | MAPTKMT2AUSP2ALDH1A1ALOX15 | |
| SCHEMBL4924283 | 0.82 | PTGDR (0.44) | KMT2AALDH1A1KDM4EPTGDRPTGES | |
| SCHEMBL4923185 | 0.82 | PTGDR (0.42) | KMT2AALDH1A1KDM4ESMN1; SMN2PTGDR | |
| SCHEMBL4926153 | 0.81 | PTGDR (0.41) | MAPTKMT2AUSP2ALDH1A1ALOX15 | |
| SCHEMBL4924502 | 0.80 | PTGES (0.40) | PTGDRPTGESPPARGTP53POLB | |
| SCHEMBL4918381 | 0.78 | MAPT (0.46) | MAPTKMT2AUSP2ALDH1A1ALOX15 | |
| SCHEMBL4925246 | 0.76 | SLC6A4 (0.37) | KMT2APTGDRPTGESPPARGGAA | |
| SCHEMBL4922669 | 0.76 | PTGDR (0.44) | KMT2AALDH1A1PTGDRPTGESPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1844013-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077364-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | MAPT 89/4885KMT2A 3954/4885USP2 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.